Replication-dependent and -independent camptothecin cytotoxicity of seven human colon tumor cell lines.
Anticancer inhibitors of topoisomerase I (TOP1, EC 5.99.1.2) cause the reversible stabilization of the TOP1-DNA covalent complex (cleavable complex). The cleavable complex can be converted into a double-strand break, the presumed cytotoxic lesion, by active replication forks. Cytotoxicity independent of DNA replication has also been demonstrated, and suggested to have possible clinical significance. To assess the importance of the replication-independent mechanism of camptothecin (CPT) cytotoxicity we have analyzed replication-dependent and replication-independent cytotoxicity following a brief CPT treatment (40 min) of seven human colon tumor cell lines. The cell lines were exposed to CPT in the presence or absence of aphidicolin, an inhibitor of DNA polymerases alpha, delta or epsilon. The seven cell lines responded similarly to CPT: treatments of less than 0.5 microM caused cytotoxicity only when DNA replication was ongoing, as evidenced by a plateau in the cytotoxicity curve corresponding to the S-phase fraction and the prevention of this cytotoxicity by aphidicolin cotreatment; at higher CPT doses, the cytotoxicity exceeded the S-phase fraction and was not prevented by aphidicolin. The CPT sensitivity among the cell lines, measured as the concentration required to inhibit cell growth by 25%, was between 0.17 and 0.43 microM without aphidicolin and 2-10 microM with aphidicolin cotreatment; with aphidicolin in cotreatment, 20-fold greater CPT concentrations were required, on average among the cell lines, to achieve cytotoxicity equivalent to CPT treatment alone. The potential of the lower dose and longer duration treatments of camptothecins used in the clinical setting to produce cytotoxicity independent of DNA replication is discussed.
Borovitskaya
A E
AE
Department of Biochemistry and Molecular Biology, Uniformed Services University of the Health Sciences, Bethesda, MD 20814-4799, USA.
D'Arpa
P
P
D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology*; D002166:Camptothecin / Q000494:pharmacology*; D004249:DNA Damage; D004261:DNA Replication; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D006801:Humans; D016196:S Phase / Q000187:drug effects; D014407:Tumor Cells, Cultured
D000972:Antineoplastic Agents, Phytogenic; D004791:Enzyme Inhibitors; D002166:Camptothecin